0001213900-22-002831.txt : 20220120 0001213900-22-002831.hdr.sgml : 20220120 20220120160019 ACCESSION NUMBER: 0001213900-22-002831 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220120 FILED AS OF DATE: 20220120 DATE AS OF CHANGE: 20220120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tiziana Life Sciences Ltd CENTRAL INDEX KEY: 0001723069 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38723 FILM NUMBER: 22542262 BUSINESS ADDRESS: STREET 1: 3RD FLOOR, 11-12 ST. JAMES'S SQUARE CITY: LONDON, ENGLAND STATE: X0 ZIP: SW1Y 4LB BUSINESS PHONE: 0044(0) 207-495-2379 MAIL ADDRESS: STREET 1: 3RD FLOOR, 11-12 ST. JAMES'S SQUARE CITY: LONDON, ENGLAND STATE: X0 ZIP: SW1Y 4LB FORMER COMPANY: FORMER CONFORMED NAME: Tiziana Life Sciences plc DATE OF NAME CHANGE: 20171116 6-K 1 ea154249-6k_tizianalife.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

January 2022

 

 

 

Commission File Number:  0001723069

 

 

 

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

9th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

  

 

 

 

 


 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On January 18, 2022, Tiziana Life Sciences Ltd. (the “Company”) entered into a Separation and Release Agreement (the “Separation Agreement”) with Dr. Neil Graham (the “Executive”), the Company’s Chief Medical Officer, in connection with his resignation from the Company for personal reasons. In connection with entry into the Separation Agreement, the Executive and Company agreed to, among other things the Executive’s release of all claims related to the Executive’s employment with the Company and termination thereof.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  TIZIANA LIFE SCIENCES LTD
       
       
Date: January 20, 2022 By:  /s/ Kunwar Shailubhai
    Name:  Kunwar Shailubhai
    Title: Chief Executive Officer

 

 

2